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Induced sputum differential cell counts have been advocated as a method of non-invasively assessing airway 
inflammation in asthma and other airway diseases. Since sputum induction usually involves delivering hypertonic 
saline via a high output ultrasonic nebulizer there have been concerns about its safety in asthma. There are relatively 
little data on the effects of sputum induction in large numbers of patients. We have examined the success rate and 
effect of sputum induction on forced expiratory volume in 1 set (FEV,) in 100 inductions performed on 79 patients 
using a low output nebulizer. Thirty-seven patients had asthma, 29 had miscellaneous conditions (mainly chronic 
cough) and 13 were subjects without respiratory symptoms. Sputum was induced 10 min after 200,~g of inhaled 
salbutamol by sequential 5-min inhalations of 3, 4 and 5% saline delivered via a Fisoneb ultrasonic nebulizer and 
FEV, was measured after each inhalation. Sputum induction resulted in a sample suitable for analysis in 92% of 
asthmatics, 90% of those with miscellaneous conditions and 100% of normal subjects. The mean (SEM) maximum per 
cent fall in FEV, was 5.4% (0. l), 4.3% (1 .O) and 2.6% (1.1) in subjects with asthma, miscellaneous conditions and in 
asymptomatic subjects respectively. Only 13 inductions resulted in a >lO% fall in FEV,, and only three of these 
resulted in a >20% fall. The maximum per cent fall in FEV, did not correlate with baseline FEV, % predicted 
(Y= - 0.17), the log sputum eosinophil count (u= - @12), or the methacholine PC,, (r= - 0 14). We conclude that 
sputum induction using a relatively low output ultrasonic nebulizer with premeditation with salbutamol is successful 
and safe in the majority of patients with asthma and other airway conditions. 
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Introduction 
Sputum induction as a non-invasive method of investigat- 
ing lower airways inflammation in asthma was first sug- 
gested by Pin et al. in 1992 (1). Since then a number of 
different methods for induction have been advocated. The 
different protocols vary in the output of the nebulizer, 
duration of nebulization and the concentration of saline 
used (l-3). Relatively little is known about the safety of 
these protocols in subjects with asthma. 
Hypertonic saline has previously been used in broncho- 
provocation tests, so there have been concerns about its 
safety in subjects with asthma (4). We have examined the 
effect of sputum induction using a low output ultrasonic 
nebulizer in 100 consecutive inductions performed on 79 
subjects. We have compared the effect of sputum induction 
on forced expiratory volume in 1 set (FEV,) in subjects 
with asthma, miscellaneous airway conditions and in sub- 
jects with no respiratory symptoms and have investigated 
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whether the change in FEV, was related to the baseline 
FEV, % predicted, methacholine airways responsiveness or 
sputum eosinophil count. 
Methods 
SUBJECTS 
One hundred consecutive inductions were performed on 79 
patients and volunteers referred from general respiratory 
clinics. Thirty-seven patients had a diagnosis of asthma, 29 
patients had miscellaneous airways conditions (12 with 
cough of unknown cause, seven with eosinophilic bronchi- 
tis, four with sarcoidosis and six with other miscellaneous 
respiratory conditions) and 13 subjects had no history of 
asthma or other respiratory symptoms and a methacholine 
PC,, of greater than 8 mg ml - i. Asthma was diagnosed in 
subjects with consistent symptoms and one or more of the 
following: a > 15% increase in FEV, 10 min after 2OOpg 
inhaled salbutamol, maximum within day peak expiratory 
flow variability of >20% or a methacholine PC,, 
<8mgml-i. Eleven asthmatic subject and six normal 
subjects had two inductions; one asthmatic had three 
inductions; and one had four inductions. Subjects’ details 
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TABLE 1. Baseline subject characteristics and mean (SEM) maximum percentage fall in FEV, 
Asthma Miscellaneous Normals 
Total number of subjects (men) 
Mean (years) age 
Range 
Present smokers/ex-smokers 
Inhaled steroids (n) 
Inductions (n) 
Successful (%) 
FEV, (% pred.) 
Amplitude % mean (mean) 
Methacholine PC,, (mg ml - ‘)* 
Sputum eosinophil count (%)* 
Mean max. fall in FEV, 
>lO% fall in FEV, (%) 
>20% fall in FEV, (%) 
36 (16) 29 (12) 13 (6) 
45.6 50.2 33.5 
15-65 15-76 19-54 
311 110 o/o 
17 2 0 
53 29 18 
92.5 89.7 100 
82.6 90.9 104.5 
30.7 10.6 6.5 
1.6 12.3 >16 
4.1 1.2 0.2 
5.4 (0.1) 4.3 (1.0) 2.6 (1.1) 
17.0 10.3 5.6 
3.8 3.4 0 
*Geometric mean. 
are summarized in Table 1. Sputum inductions were per- 
formed for clinical reasons and as part of clinical trials. The 
protocol of the trials was approved by the Leicestershire 
Ethics Committee and subjects gave full informed consent 
to participate. 
using a Shandon cytocentrifuge. Cytospins were stained 
with the Romanowski stain and two blinded observers 
counted between 200 and 400 non-squamous cells. 
A successful induction was considered to be one that 
produced sputum that was suitable for analysis. 
MEASUREMENTS STATISTICS 
Bronchoprovocation testing was performed using the tidal 
breathing method as previously described (5). Sputum was 
induced using a modified version of the technique described 
by Pin et al. (1,6). Subjects’ FEV, was measured using a 
micro-plus spirometer (Micromedical, Gillingham, U.K.), 
before and 10 min after treatment with 2OOpg of salbuta- 
mol inhaled via a volumatic. Induction was then performed 
using 5 ml of 3% saline nebulized via a Fisoneb (Clement 
Clark, Harlow, U.K.) ultrasonic nebulizer (output 
0.9 ml min - i, mean mass diameter 5.6pm) for 5 min. 
FEV, was then remeasured; the subject was then asked to 
blow their nose and rinse their mouth and cough into a 
sterile container. If the fall in FEV, was less than 10% 
compared to the post-bronchodilator FEV, the induction 
was repeated using 4% followed by 5% saline. If the FEV, 
fall was between 10 and 20% the previous concentration of 
saline was used, if the fall was greater than 20% then the 
procedure was discontinued. 
Data are presented as mean and standard error of the mean 
(SEM). The baseline FEV, was defined as the post- 
salbutamol reading and both the FEV, % predicted and the 
percentage fall in FEV, were calculated in relation to this. 
Methacholine PC,, and sputum differential eosinophil 
counts were log-transformed to give a normal distribution 
and described as the geometric mean. The change in FEV, 
after each concentration was expressed as percentage 
change from baseline (post-salbutamol) and the maximum 
fall in FEV, was defined as maximum decrease observed 
after any concentration of hypertonic saline. The change in 
FEV, after each concentration and the maximum percent- 
age fall in FEV, were compared between groups by one- 
way ANOVA. If no fall was observed it was assigned as no 
change. The maximum fall in FEV, was correlated with the 
log eosinophil count, the log methacholine PC,, and FEV, 
% predicted using Pearson’s correlation coefficient. 
Sputum was processed as has been previously described 
(6). Briefly sputum was selected from saliva, weighed and 
dispersed using four volumes 0.1% dithiothreitol. After 
15 min gentle rocking the cell suspension was diluted with a 
further four volumes of Dulbecco’s phosphate-buffered 
saline and filtered through a 48 pg nylon gauze. Squamous 
cell count and total cell count were obtained using a 
Neubauer haemocytometer and cell viability was assessed 
by the trypan blue exclusion method. The cell suspension 
was adjusted to 0.75 x lo6 cells ml - ’ and 75 ~1 cell suspen- 
sion was used to prepare cytospins at 450 rpm for 6 min 
Results 
Sputum induction was successful (as defined above) in 92% 
of patients with asthma, 90% of patients with miscellaneous 
conditions and 100% of normal subjects. The mean (SEM) 
maximum fall in FEV, was 5.4% (0.1) in asthmatics, 4.3% 
(1.0) in those with miscellaneous conditions and 2.6% (1.1) 
in the normal subjects (P>O.O5; Table 1). Thirteen induc- 
tions (nine on subjects with a diagnosis of asthma, three on 
subjects with a miscellaneous diagnosis and one on a 
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TABLE 2. Mean (SEM) percentage change in FEV, following 3, 4 and 5% saline in each group 
3% saline 4% saline 5% saline 
Asthmatics - 0.80 (0.91) - 1.12 (1.01) - 0.45 (1.30) 
Miscellaneous - 1.37 (0.71) - 1.00 (0.77) - 2.84 (1.10) 
Controls 0.24 (1.05) 0.11 (1.59) 1.80 (0.77) 
control subject) resulted in a greater than 10% fall in FEV,. 
Six developed the fall after 3% saline, four after 4% saline 
and three after 5% saline. Three patients (all with asthma) 
had a greater than 20% fall in their FEV, (maximum 23%). 
One developed the fall in FEV, after 4% saline, the other 
two after 5% saline. Five subjects with a greater than 10% 
fall had repeat inductions which resulted in three of these 
subjects again dropping their baseline FEV, by greater than 
10%. All subjects recovered promptly to within 5% of their 
baseline FEV, 10 minutes after a further 200 pg of inhaled 
salbutamol and there were no long-term sequelae. The 
mean change in FEV, in each group with each concen- 
tration of saline did not differ significantly between the 
groups (P>O.O5; Table 2). 
There was no correlation between the maximal fall in 
FEV, and either FEV, % predicted (r= - 0.17) the log 
sputum eosinophil count (r= - 0.12) or the log PC,, 
(r= - 0 14). 
Discussion 
We have shown that, after pretreatment with salbutamol, 
sputum induction using a low output nebulizer is both safe 
and successful. Our success rates are higher than those 
reported in smaller studies using essentially the same spu- 
tum induction protocols (1). This may reflect a lower 
threshold for accepting sputum as suitable for analysis or 
the fact that we carried out sputum induction irrespective of 
whether the subject could produce sputum spontaneously, 
while others (1) have restricted the technique to subjects 
unable to spontaneously produce sputum. 
Two further large studies (7,s) have addressed the issue 
of safety of sputum induction using hypertonic saline. Both 
of these used slightly different induction protocols to our- 
selves. Wong et al. (7) administered 3% saline via a rela- 
tively high output nebulizer (output 2.4 ml min - ‘) and did 
not measure the FEV, until the end of the 20-min induc- 
tion, whereas de la Fuente et al. (8) used a similar protocol 
to ourselves with increasing concentrations of hypertonic 
saline, but again used a relatively high output nebulizer 
(output 2.4 ml min- ‘). Wong et al. reported a higher 
incidence of severe bronchoconstriction and a slightly 
greater mean maximum fall in FEV, in subjects with 
asthma (7) while de la Fuente et al. reported a similar mean 
maximal fall in FEV, but a slightly higher proportion of 
subjects with a greater than 10% fall in FEV,. Broncho- 
constriction in response to inhaled hypertonic saline in 
subjects with asthma is related to the total dose delivered 
and the rate of delivery (4) so reduced nebulization times 
and (in our case) a low output of the nebulizer would be 
expected to cause less bronchoconstriction. Furthermore, 
our more frequent monitoring of FEV, during, the pro- 
cedure may result in recognition of bronchoconstriction 
before it becomes severe since subjects with asthma typi- 
cally develop a fall in their FEV, during the first 15 ml of 
nebulized hypertonic saline (4). It is notable that Wong and 
colleagues have now recommended similar more frequent 
monitoring (7). Our use of a low output nebulizer did not 
result in a lower success rate than that of de la Fuente et al. 
or other protocols using high output nebulizers (2,3) sug- 
gesting that these more aggressive induction protocols do 
not have any particular advantage. Such techniques may 
also have the disadvantage of causing neutrophilic airway 
inflammation (9,lO). 
The safety of sputum induction would be increased if it 
were possible to identify subject characteristics that pre- 
dicted a bronchoconstrictor response to hypertonic saline. 
We were unable to find a relationship between change in 
FEV, in response to hypertonic saline and either the 
baseline FEV,, the sputum eosinophil count or the metha- 
choline airway responsiveness. This may be because the 
effect of hypertonic saline was so small in our study. Wong 
et al. (7) found a more clear-cut relationship between 
change in FEV, and all three features of asthma, perhaps 
because the between subject variability in the response to 
hypertonic saline was more marked and the subjects had a 
wider range of baseline airway responsiveness. 
As with most other studies, our subjects with asthma had 
relatively mild stable disease and this might have limited the 
effect of nebulized hypertonic saline. In support of this 
Pizzichini et al. (11) have recently shown that sputum 
induction using a low output ultrasonic nebulizer in un- 
stable asthma is associated with a >20% fall in FEV, in up 
to one-third of patients despite salbutamol premeditation 
and the use of reduced volumes and concentrations of 
hypertonic saline. There was no clear association with a low 
baseline FEV, and high sputum eosinophil count, although 
the risk appeared to be highest in subjects using frequent 
and high doses of inhaled &agonists over the preceding 
24 h. De la Fuente et al. (8) also found a higher incidence 
of severe adverse events in the severe asthmatics (FEV, 
< 1 litre) during their preliminary study and in fact excluded 
these subjects from the full study. These findings emphasize 
the importance of careful monitoring of patients with 
unstable asthma during sputum induction. 
In conclusion, we have shown that, with salbutamol 
premeditation and careful monitoring of FEV, in clinically 
stable patients, sputum induction is safe and that using a 
low output nebulizer has no detrimental effect on the 
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success rate. In this clinical setting we were unable to 
identify any particular subject characteristics associated 
with an increased risk of significant bronchospasm. 
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